- Anti-nucleocapsid antibody response in COVID-LT group was positive in 80% of the cases. However, the level detected in the COVID-LT group was significantly lower in comparison to the level detected in the COVID-immunocompetent cohort (3.73 vs. 7.36, p<0.001).

- Anti-spike-protein antibody response showed no difference in positivity rates between the COVID-LT and the COVID-immunocompetent cohorts (97.1% vs. 100%, p=0.314).

- The majority of LT recipients is able to produce functional antibodies against SARS-CoV-2 after a confirmed SARS-CoV2 infection. This neutralizing ability is associated with the presence of anti-nucleocapsid antibodies.

- The findings in the non-COVID-LT group confirm that both assays show specificity for detection of SARS-CoV-2 antibodies in the LT population.